Hepatocellular Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Condition:   Hepatocellular Carcinoma Interventions:   Drug: N Acetylcysteine;   Drug: Dexamethasone;   Other: Placebo Sponsor:   Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition:   Hepatocellular Carcinoma (HCC) Interventions:   Drug: Durvalumab;   Drug: Bevacizumab;   Procedure: Transarterial Radioembolization (TARE) Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Conditions:   Hepatocellular Carcinoma Non-resectable;   Portal Vein Tumor Thrombus;   Immune Checkpoint Inhibitors Interventions:   Drug: Cadonilimab;   Radiation: Stereotactic radiotherapy;   Drug: Renvatinib Sponsor:   First Affiliated Hospital of Guangxi Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Condition:   Hepatocellular Carcinoma Interventions:   Drug: N Acetylcysteine;   Drug: Dexamethasone;   Other: Placebo Sponsor:   Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition:   Hepatocellular Carcinoma (HCC) Interventions:   Drug: Durvalumab;   Drug: Bevacizumab;   Procedure: Transarterial Radioembolization (TARE) Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Conditions:   Hepatocellular Carcinoma Non-resectable;   Portal Vein Tumor Thrombus;   Immune Checkpoint Inhibitors Interventions:   Drug: Cadonilimab;   Radiation: Stereotactic radiotherapy;   Drug: Renvatinib Sponsor:   First Affiliated Hospital of Guangxi Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Condition:   Hepatocellular Carcinoma Interventions:   Drug: N Acetylcysteine;   Drug: Dexamethasone;   Other: Placebo Sponsor:   Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition:   Hepatocellular Carcinoma (HCC) Interventions:   Drug: Durvalumab;   Drug: Bevacizumab;   Procedure: Transarterial Radioembolization (TARE) Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Conditions:   Hepatocellular Carcinoma Non-resectable;   Portal Vein Tumor Thrombus;   Immune Checkpoint Inhibitors Interventions:   Drug: Cadonilimab;   Radiation: Stereotactic radiotherapy;   Drug: Renvatinib Sponsor:   First Affiliated Hospital of Guangxi Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
Condition:   Hepatocellular Carcinoma Interventions:   Drug: N Acetylcysteine;   Drug: Dexamethasone;   Other: Placebo Sponsor:   Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition:   Hepatocellular Carcinoma (HCC) Interventions:   Drug: Durvalumab;   Drug: Bevacizumab;   Procedure: Transarterial Radioembolization (TARE) Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Conditions:   Hepatocellular Carcinoma Non-resectable;   Portal Vein Tumor Thrombus;   Immune Checkpoint Inhibitors Interventions:   Drug: Cadonilimab;   Radiation: Stereotactic radiotherapy;   Drug: Renvatinib Sponsor:   First Affiliated Hospital of Guangxi Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition:   Hepatocellular Carcinoma (HCC) Interventions:   Drug: Durvalumab;   Drug: Bevacizumab;   Procedure: Transarterial Radioembolization (TARE) Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials